Related Experiment Video
Updated: Nov 17, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.5K
It's time to die: BH3 mimetics in solid tumors.
1Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany.
Biochimica Et Biophysica Acta. Molecular Cell Research
|February 18, 2021
Summary
Cancer cells evade apoptosis, a key cell removal process, by overexpressing Bcl-2 proteins. This review explores BH3 mimetics targeting Mcl-1 and Bcl-xL in solid tumors.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Apoptosis is crucial for tissue homeostasis, but cancer cells evade it.
- The Bcl-2 protein family regulates apoptosis; anti-apoptotic members promote cancer cell survival.
- Overexpression of Mcl-1 and Bcl-xL is common in solid tumors, conferring resistance to apoptosis.
Purpose of the Study:
- To review the role of Mcl-1 and Bcl-xL in solid tumors.
- To compare BH3 mimetics targeting Mcl-1 and Bcl-xL for cancer therapy.
Main Methods:
- Literature review of studies on apoptosis regulation in cancer.
- Analysis of the role of Mcl-1 and Bcl-xL in solid tumor progression.
- Comparison of the mechanisms and clinical potential of BH3 mimetics.
Main Results:
- Mcl-1 and Bcl-xL are frequently overexpressed in solid tumors, contributing to therapeutic resistance.
- BH3 mimetics represent a promising therapeutic strategy by inhibiting anti-apoptotic Bcl-2 proteins.
- Venetoclax, a BH3 mimetic, is approved for leukemia, highlighting the potential of this drug class.
Conclusions:
- Targeting Mcl-1 and Bcl-xL with BH3 mimetics is a viable strategy for treating solid tumors.
- Further research and development of BH3 mimetics are needed to overcome resistance mechanisms in solid tumors.
